Symbiotec Pharmalab Shares Rise 6% on US Distribution Deal
Symbiotec Pharmalab shares rose nearly 6% after its subsidiary secured exclusive rights to distribute two injectable products in the US, targeting a $288 million market. The deal involves development, regulatory approval, and profit-sharing milestones.
Read